DDInter704 DDInter899
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Everolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Everolimus {u} (Compound) treats {v} (Disease) kidney cancer
Everolimus {u} (Compound) binds {v} (Gene) FKBP1A
Everolimus {u} (Compound) upregulates {v} (Gene) USP20
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2D6 Inhibitors
Everolimus {u} (Compound) downregulates {v} (Gene) ATF1
Everolimus {u} (Compound) causes {v} (Side Effect) Pericardial effusion
Everolimus (Compound) resembles Pimecrolimus (Compound)
Everolimus (Compound) resembles Temsirolimus (Compound)
Everolimus (Compound) treats kidney cancer (Disease)
Everolimus (Compound) binds FKBP1A (Gene)
Everolimus (Compound) upregulates USP20 (Gene)
Everolimus (Compound) is included by Cytochrome P450 2D6 Inhibitors (Pharmacologic Class)
Everolimus (Compound) downregulates ATF1 (Gene)
Everolimus (Compound) causes Pericardial effusion (Side Effect)